Marrache
Sean Marrache, Athens, GA US
Patent application number | Description | Published |
---|---|---|
20140303081 | APOPTOSIS-TARGETING NANOPARTICLES - Nanoparticles include a core and one or more targeting moieties, as well as one or more contrast agents or one or more therapeutic agents. The contrast agents or therapeutic agents may be contained or embedded within the core. If the nanoparticle includes therapeutic agents, the agents are preferably released from the core at a desired rate. The core may be biodegradable and may release the agents as the core is degraded or eroded. The targeting moieties preferably extend outwardly from the core so that they are available for interaction with cellular components, which interactions will target the nanoparticles to the appropriate cells, such as apoptotic cells; organelles, such as mitochondria; or the like. The targeting moieties may be tethered to the core or components that interact with the core. | 10-09-2014 |
Sean Marrache, Portland, OR US
Patent application number | Description | Published |
---|---|---|
20150374714 | GENERATION OF FUNCTIONAL DENDRITIC CELLS - Nanoparticles containing a photosensitizer configured to generate a reactive oxygen species when exposed to an appropriate wavelength of light can be used to enhance immunogenicity of cancer cells, such as breast cancer cells. Such enhanced immunogenicity cancer cells, or supernatants thereof, can be used to activate dendritic cells or cause dendritic cells to produce INF-gamma. Nanoparticles having mitochondria-targeting moieties are more effective at enhancing the immunogenicity of the cancer cells, or causing the dendritic cells to produce IFN-gamma, than nanoparticle lacking mitochondria-targeting moieties or free photo sensitizer. | 12-31-2015 |
Sean M. Marrache, Athens, GA US
Patent application number | Description | Published |
---|---|---|
20160022825 | NANOPARTICLES FOR MITOCHONDRIAL TRAFFICKING OF AGENTS - Nanoparticles include a core, a hydrophilic layer around the core, and one or more mitochondrial targeting moieties, and may optionally include one or more contrast agents or one or more therapeutic agents. For effective mitochondrial targeting the nanoparticles have a diameter of about 200 nm or less or have a zeta potential of about 0 mV or more. | 01-28-2016 |